

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4439471

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SANDU PITARU	07/06/2014
JAVIER GANZ	06/29/2014
DANIEL OFFEN	06/05/2014
ELDAD MELAMED	06/20/2014
RECEIVING PARTY DATA	
Name:	RAMOT AT TEL-AVIV UNIVERSITY LTD.
Street Address:	P.O. BOX 39296
City:	TEL AVIV
State/Country:	ISRAEL
Postal Code:	61392
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14359623
CORRESPONDENCE DATA	
Fax Number:	(202)737-3528
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	202-628-5197
Email:	PAMELA@BROWDYNEIMARK.COM
Correspondent Name:	BROWDY AND NEIMARK, PLLC
Address Line 1:	1625 K STREET, NW
Address Line 2:	SUITE 1100
Address Line 4:	WASHINGTON, D.C. 20006
ATTORNEY DOCKET NUMBER:	PITARU3
NAME OF SUBMITTER:	ALLEN C. YUN
SIGNATURE:	/ACY/
DATE SIGNED:	06/01/2017
Total Attachments: 5	
source=2017-06-01ExecutedAssignment_PITARU3#page1.tif	
source=2017-06-01ExecutedAssignment_PITARU3#page2.tif	

source=2017-06-01ExecutedAssignment_PITARU3#page3.tif

source=2017-06-01ExecutedAssignment_PITARU3#page4.tif

source=2017-06-01ExecutedAssignment_PITARU3#page5.tif

ASSIGNMENT

This Assignment is made and executed by:

Sandu PITARU
46 Ben Eliezer Street
Ramat Gan 52290
Israel

Javier GANZ
97/10 Shlomo Hamelech Street
Tel Aviv 64512
Israel

Daniel OFFEN
Kfar Haroeh 38955
Israel

Eldad MELAMED
44 Tagor Street
Tel Aviv 69341
Israel

(hereinafter "Assignors"), to and in favor of RAMOT AT TEL-AVIV UNIVERSITY LTD. having a business address of P.O. Box 39296, 61392 Tel Aviv, Israel. (hereinafter "Assignee").

Whereas each of the Assignors desires to assign his entire right, title and interest in and to the invention described in the nonprovisional patent application for a United States Patent entitled "STEM CELL-DERIVED NEURAL CELLS FOR CELL THERAPY IN NEUROLOGICAL DISORDERS" which claims priority to as a 371 of international of PCT/IL2012/050471, filed on November 21, 2012, which claims priority to US provisional patent application number 61/561,955, filed on November 21, 2011 (hereinafter the "Patent Application") and all patents, patent applications and the like on the invention to Assignee for valuable consideration; and

Whereas Assignee has provided such valuable consideration to the Assignors;

Accordingly, Assignors each warrant, covenant and agree as follows:

1. Each of the Assignors hereby sells, assigns and conveys to Assignee such Assignor's entire right, title and interest in and to the invention described in the Patent Application, including the Patent Application itself and all substitute, continuation, continuation-in-part and divisional applications based in whole or in part on the Patent Application, and including all patents resulting therefrom and all reissues and extensions thereof, and including any and all rights of priority resulting from the filing of any such applications within the United States.

2. Each of the Assignors hereby sells, assigns and conveys to Assignee such Assignor's entire right, title and interest in all counterparts to the Patent Application that have been or may be filed outside the United States or under the Patent Cooperation Treaty, whether pursued as a patent, an inventor's certificate, a utility model or the like, including all rights of

ASSIGNMENT

Docket No. _____

Title: "STEM CELL-DERIVED NEURAL CELLS FOR
CELL THERAPY IN NEUROLOGICAL DISORDERS"

U.S. Serial No.

priority based on the Patent Application, further including all continuation, continuation-in-part and divisional applications based in whole or in part on the non-U.S. counterparts, and still further including all patents, inventor's certificates, utility models, reissues and extensions resulting from any of the non-U.S. counterparts.

3. Each of the Assignors hereby grants to Assignee the sole and exclusive right to prosecute the Patent Application and all related applications as described in Paragraphs 1 and 2 above, as well as any opposition proceedings, reissue applications, reexaminations, and nullity or invalidity proceedings. Each of the Assignors authorizes all governmental bodies having the power to issue patents, inventor's certificates or utility models to issue a patent, inventor's certificate or utility model based on the Patent Application or any related applications as described in Paragraphs 1 and 2 above in the name of Assignee.

4. Each of the Assignors agrees upon request and without further consideration, but at Assignee's expense: (a) to assist Assignee in prosecuting the Patent Application and all related applications as described in Paragraphs 1 and 2 above, as well as opposition proceedings, reissue applications, reexaminations, and nullity or invalidity proceedings; (b) to provide Assignee with information concerning the Patent Application and the related applications described in Paragraphs 1 and 2 above to enable Assignee to obtain, secure and protect all of the rights, title and interest sold, assigned, conveyed and granted under this Assignment (the "Assigned Assets"); (c) to sign papers, take oaths and testify in legal proceedings to enable Assignee to obtain, secure and protect the Assigned Assets; and (d) to perform all acts reasonably necessary to enable Assignee to obtain, secure and protect the Assigned Assets, including assistance in any proceedings pertaining to the Patent Application and the related applications described in Paragraphs 1 and 2 above or to their enforcement.

5. Each of the Assignors warrants and covenants that such Assignor has the full right to sell, assign and convey the Assigned Assets, that all of the Assigned Assets are free and clear of all mortgages, liens, security interests, charges, claims, royalty obligations and encumbrances of any nature whatsoever and that the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

6. Assignee may assign the Assigned Assets in whole or in part. All references herein to Assignee include any successors or assigns of Assignee.

7. Each of the Assignors acknowledges that Assignee has paid valuable consideration for the Assigned Assets.

ASSIGNMENT

Docket No. _____

Title: "STEM CELL-DERIVED NEURAL CELLS FOR
CELL THERAPY IN NEUROLOGICAL DISORDERS"

U.S. Serial No. _____

06 July 2014
Date

[Signature]
Sandu PITARU
[Signature]
Witness

Date

Javier GANZ

Witness

5/6/14
Date

[Signature]
Daniel OFFEN
[Signature]
Witness

Date

Eldad MELAMED

Witness

ASSIGNMENT

Docket No. _____

Title: "STEM CELL-DERIVED NEURAL CELLS FOR
CELL THERAPY IN NEUROLOGICAL DISORDERS"

U.S. Serial No. _____

Date

Sandu PITARU

Witness

June 29th, 2014

Date

Javier GANZ

Witness

Date

Daniel OFFEN

Witness

Date

Eldad MELAMED

Witness

ASSIGNMENT

Title: "STEM CELL-DERIVED NEURAL CELLS FOR
CELL THERAPY IN NEUROLOGICAL DISORDERS"

U.S. Serial No.

Docket No. _____

Date

Sandu PITARU

Witness

Date

Javier GANZ

Witness

Date

Daniel OFFEN

Witness

June 20, 2014
Date

Eldad Melamed
Eldad MELAMED

[Signature]
Witness